Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 20

1.

Cannabidiolic acid, a major cannabinoid in fiber-type cannabis, is an inhibitor of MDA-MB-231 breast cancer cell migration.

Takeda S, Okajima S, Miyoshi H, Yoshida K, Okamoto Y, Okada T, Amamoto T, Watanabe K, Omiecinski CJ, Aramaki H.

Toxicol Lett. 2012 Nov 15;214(3):314-9. doi: 10.1016/j.toxlet.2012.08.029. Epub 2012 Sep 8.

2.

Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis.

Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE, Ganju RK.

Cancer Prev Res (Phila). 2011 Jan;4(1):65-75. doi: 10.1158/1940-6207.CAPR-10-0181. Epub 2010 Nov 19.

3.

Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer.

Qamri Z, Preet A, Nasser MW, Bass CE, Leone G, Barsky SH, Ganju RK.

Mol Cancer Ther. 2009 Nov;8(11):3117-29. doi: 10.1158/1535-7163.MCT-09-0448. Epub 2009 Nov 3.

4.

Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.

van Hasselt JG, van den Heuvel MM, Schellens JH, Beijnen JH, Brandsma D, Huitema AD.

J Palliat Care. 2012 Spring;28(1):60-1. No abstract available.

PMID:
22582474
5.

Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion.

Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X, Ganju RK.

PLoS One. 2011;6(9):e23901. doi: 10.1371/journal.pone.0023901. Epub 2011 Sep 7.

6.

Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.

Pisanti S, Malfitano AM, Grimaldi C, Santoro A, Gazzerro P, Laezza C, Bifulco M.

Best Pract Res Clin Endocrinol Metab. 2009 Feb;23(1):117-31. doi: 10.1016/j.beem.2009.02.001. Review.

PMID:
19285265
7.

Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.

Donadelli M, Dando I, Zaniboni T, Costanzo C, Dalla Pozza E, Scupoli MT, Scarpa A, Zappavigna S, Marra M, Abbruzzese A, Bifulco M, Caraglia M, Palmieri M.

Cell Death Dis. 2011 Apr 28;2:e152. doi: 10.1038/cddis.2011.36.

8.

Betulinic acid targets YY1 and ErbB2 through cannabinoid receptor-dependent disruption of microRNA-27a:ZBTB10 in breast cancer.

Liu X, Jutooru I, Lei P, Kim K, Lee SO, Brents LK, Prather PL, Safe S.

Mol Cancer Ther. 2012 Jul;11(7):1421-31. doi: 10.1158/1535-7163.MCT-12-0026. Epub 2012 May 2.

9.

Cannabinoid receptor as a novel target for the treatment of prostate cancer.

Sarfaraz S, Afaq F, Adhami VM, Mukhtar H.

Cancer Res. 2005 Mar 1;65(5):1635-41.

10.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL 3rd, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, Vanderah TW.

J Bone Miner Res. 2013 Jan;28(1):92-107. doi: 10.1002/jbmr.1732.

11.

Cannabinoid receptor activation induces apoptosis through tumor necrosis factor alpha-mediated ceramide de novo synthesis in colon cancer cells.

Cianchi F, Papucci L, Schiavone N, Lulli M, Magnelli L, Vinci MC, Messerini L, Manera C, Ronconi E, Romagnani P, Donnini M, Perigli G, Trallori G, Tanganelli E, Capaccioli S, Masini E.

Clin Cancer Res. 2008 Dec 1;14(23):7691-700. doi: 10.1158/1078-0432.CCR-08-0799.

12.
13.

Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.

Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD.

Carcinogenesis. 2010 Sep;31(9):1584-91. doi: 10.1093/carcin/bgq151. Epub 2010 Jul 25.

14.

O-1602, an atypical cannabinoid, inhibits tumor growth in colitis-associated colon cancer through multiple mechanisms.

Kargl J, Haybaeck J, Stančić A, Andersen L, Marsche G, Heinemann A, Schicho R.

J Mol Med (Berl). 2013 Apr;91(4):449-58. doi: 10.1007/s00109-012-0957-1. Epub 2012 Sep 11.

15.

The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation.

Piñeiro R, Maffucci T, Falasca M.

Oncogene. 2011 Jan 13;30(2):142-52. doi: 10.1038/onc.2010.417. Epub 2010 Sep 13.

PMID:
20838378
16.

Antiproliferative mechanism of a cannabinoid agonist by cell cycle arrest in human gastric cancer cells.

Park JM, Xian XS, Choi MG, Park H, Cho YK, Lee IS, Kim SW, Chung IS.

J Cell Biochem. 2011 Apr;112(4):1192-205. doi: 10.1002/jcb.23041.

PMID:
21312237
17.

A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW.

Life Sci. 2010 Apr 24;86(17-18):646-53. doi: 10.1016/j.lfs.2010.02.014. Epub 2010 Feb 20.

18.

Concerted action of CB1 cannabinoid receptor and deleted in colorectal cancer in axon guidance.

Argaw A, Duff G, Zabouri N, Cécyre B, Chainé N, Cherif H, Tea N, Lutz B, Ptito M, Bouchard JF.

J Neurosci. 2011 Jan 26;31(4):1489-99. doi: 10.1523/JNEUROSCI.4134-09.2011.

19.

The endogenous cannabinoid, anandamide, induces COX-2-dependent cell death in apoptosis-resistant colon cancer cells.

Patsos HA, Greenhough A, Hicks DJ, Al Kharusi M, Collard TJ, Lane JD, Paraskeva C, Williams AC.

Int J Oncol. 2010 Jul;37(1):187-93.

PMID:
20514410
20.

Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.

Curto-Reyes V, Llames S, Hidalgo A, Menéndez L, Baamonde A.

Br J Pharmacol. 2010 Jun;160(3):561-73. doi: 10.1111/j.1476-5381.2009.00629.x. Epub 2010 Mar 3.

Supplemental Content

Support Center